Back to results
US 2003/0152567 A1Published application
Protease for activating clotting factor VII
AssigneeAventis Behring GmbH
InventorsJuergen Roemisch, Annette Feussner, Hans-Arnold Stoehr
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAventis Behring GmbH
InventorsJuergen Roemisch, Annette Feussner, Hans-Arnold Stoehr
Estimating the term…
A protease for activating the blood clotting factor VII is described, which a) is inhibited by the presence of aprotinin, b) is increased in its activity by calcium ions and/or heparin or heparin-related substances, and c) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more brands in the molecular weight range from 50 to 75 kDa and kDa in the reduced state has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa. The proenzyme of this protease is also characterized. Further, a process for obtaining this protease and its use in hemorrhage prophylaxis or hemostasis is described. Moreover, a test system for the qualitative and quantitative detection of a protease which activates the blood clotting factor VII is described.
A protease for activating the blood clotting factor VII, which
An assay system where the protease and/or a mixture of the proenzyme and appropriate proenzyme activators are used to test the prothrombin time substituting tissue factor/thromboplastin.
An assay system where the protease and/or a mixture of the proenzyme and appropriate proenzyme activators are used to test the functionality of plasminogen activators and for quantification of the single chain plasminogen activator forms.
A stabilized factor V and stabilized factor VIII preparation, which is free of the inactive factor VIII and factor V fragments formed due to proteolytic degradation as a result of the inhibition of the protease activating the blood clotting factor VII.
A pharmaceutical preparation, which contains an amount of the protease activating the blood clotting factor VII, and/or its proenzyme, adequate for the dissolution of fibrin-containing thrombi.
Dependencies are inferred from the claim text.